Matches in Wikidata for { <http://www.wikidata.org/entity/Q106642623> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q106642623 description "clinical trial" @default.
- Q106642623 description "ensayo clínico" @default.
- Q106642623 description "ensayu clínicu" @default.
- Q106642623 description "klinisch onderzoek" @default.
- Q106642623 description "клінічне випробування" @default.
- Q106642623 description "临床试验" @default.
- Q106642623 name "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 name "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 type Item @default.
- Q106642623 label "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 label "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 prefLabel "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 prefLabel "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 P1132 Q106642623-8B22CCE2-C330-4377-B16E-8DD274756253 @default.
- Q106642623 P1476 Q106642623-C96FDDC8-EB05-4338-B9C0-5A78D5600572 @default.
- Q106642623 P2899 Q106642623-2B839335-4030-46F6-A131-3C74ED38E9BF @default.
- Q106642623 P3098 Q106642623-664C4746-3062-4F8B-9016-F6958CBA5153 @default.
- Q106642623 P31 Q106642623-77CDAFBE-5A2C-4492-BF9F-7236DB439D00 @default.
- Q106642623 P4135 Q106642623-077F094E-755A-4797-92F9-A9096B1210B3 @default.
- Q106642623 P580 Q106642623-88961BFD-ECAF-45B4-BBA0-504425AE3E9A @default.
- Q106642623 P582 Q106642623-3CFF045B-BF66-4ACB-934B-195F2A139137 @default.
- Q106642623 P6099 Q106642623-53BADF1D-4C3E-4207-B7ED-69998809C36F @default.
- Q106642623 P8005 Q106642623-80368400-EEA9-4DE9-BD36-470A82C8AF1F @default.
- Q106642623 P8363 Q106642623-B4C2CAEF-A8B7-47A0-82FB-54320279F728 @default.
- Q106642623 P1132 "+180" @default.
- Q106642623 P1476 "A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers" @default.
- Q106642623 P2899 "+18" @default.
- Q106642623 P3098 "NCT04852978" @default.
- Q106642623 P31 Q30612 @default.
- Q106642623 P4135 "+90" @default.
- Q106642623 P580 "2021-04-20T00:00:00Z" @default.
- Q106642623 P582 "2021-07-30T00:00:00Z" @default.
- Q106642623 P6099 Q42824440 @default.
- Q106642623 P8005 Q76649614 @default.
- Q106642623 P8363 Q78089383 @default.